JT3 (@Joshthe3rd_) header
JT3 (@Joshthe3rd_) profile picture

JT3

@Joshthe3rd_

Always learning from mistakes and always adapting. https://teapaw.org/t.co/ddEatJXh6c (Charts + Notes posted here as well)

 Antarctica
Joined February 2021
  • Tweets3.2K
  • Following264
  • Followers1K
933Media
Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)
*Updated* 500M+ Biotech Public Offerings 2024-2026 (6/20/26) added (CYTK) I will create a new one at YE. $XBI
Image from JT3 (@Joshthe3rd_)
JT3 (@Joshthe3rd_) profile pictureJT3@Joshthe3rd_Jun 20
1/ 500M+ biotech offerings 2024-2026 $XBI ABVX - 743M PO at 64.00 (2025) INSM - 750M PO at 96.00 (2025) PCVX - 1.3B PO at 103.00 (2024) PCVX - 632M PO at 50.00 (51.00) VKTX - 550M PO at 85.00 (2024) IONS - 500M PO at 43.50 (2024) RVMD - 750M PO at 46.00 (2024) RVMD - 1.65B PO
3
5
2
43
37,374
$TSHA 🤔
Image from JT3 (@Joshthe3rd_)
225
$TCRX cash through end of 2027. Preclin data for in-vivo tumor asset in q1 2027. If they can't raise then will be forced to strat alt. We wait for now.
259
$INO
8
385
$XBI despite the carnage still maintaining a decent trend on the daily. Should retest the 200MA daily though.
Image from JT3 (@Joshthe3rd_)
1
2
404
Days of the old XBI are behind us. Now the index has higher quality commercial/p2/3 names flush with cash. We will have dips, but willing to bet they will be less exaggerated then the ones in the past. Though high risk clinical biotechs 100% got nuked and look like the old XBI.
194
$DTIL 🥳
Image from JT3 (@Joshthe3rd_)
JT3 (@Joshthe3rd_) profile pictureJT3@Joshthe3rd_Oct 30
Replying to @Joshthe3rd_
This can be a sign of a bigger move to the upside to follow. And considering both seemed to avoid the liquidations knife pretty well + PRME gaining momentum, I like the r/r. I did work on DTIL, but am catching up on my DD for edit.
2
314
ah thats what I missed $YARW did the first initial merger offering at 7.06
Image from JT3 (@Joshthe3rd_)
210
$KRRO kind of reminds me of similarities to $RGLS.
JT3 (@Joshthe3rd_) profile pictureJT3@Joshthe3rd_Jul 16
Been thinking about all the early stage ADC biotech M&A that has happened over the last few years. I wonder if early stage RNA editing bios are next.
3
365
$VRDN 008 data in Q4
Image from JT3 (@Joshthe3rd_)
1
2
531
$XFOR $KRRO catalysts a long ways out but are in tight weekly ranges.
Image from JT3 (@Joshthe3rd_)
Image from JT3 (@Joshthe3rd_)
331
$TNXP retarded management. Just nuke the pipeline and focus only on TNX-4800. Are they trying to compete with $BHVN for having the most worthless bloated pipeline?
2
8
1,397
$SNGX Cash to 2Q 2028. Looking for strategic alternatives. 0.31 in net cash per share. High chance they will do a reverse merger. Only interested in it if it drops to the 0.15 - 0.20 area.
Image from JT3 (@Joshthe3rd_)
243
$ENTA as well doing the same
Image from JT3 (@Joshthe3rd_)
JT3 (@Joshthe3rd_) profile pictureJT3@Joshthe3rd_Oct 30
$EDIT $DTIL both riding the MA100 weekly pretty tight.
Image from JT3 (@Joshthe3rd_)
Image from JT3 (@Joshthe3rd_)
2
303
$ABOS
16
747
$EDIT $DTIL both riding the MA100 weekly pretty tight.
Image from JT3 (@Joshthe3rd_)
Image from JT3 (@Joshthe3rd_)
1
1
4
894
This can be a sign of a bigger move to the upside to follow. And considering both seemed to avoid the liquidations knife pretty well + PRME gaining momentum, I like the r/r. I did work on DTIL, but am catching up on my DD for edit.
1
3
345
$EDIT tight range
Image from JT3 (@Joshthe3rd_)
1
2
509
27% short interest. Tight range + cashed up is a deadly combo for a slow squeeze data runup.
1
3
216
October Chart Roundup (With Thoughts) joshthe3rd.substack.com/p/oc…
2
379
$ARTV lets see how fast Ra Capital reverse merges this or liquidates it.
2
353
Load more